Therefore, CTLA-4 inhibitors facilitate immune-mediated anti-tumor response by antagonizing CTLA-4/B7 interactions, enabling CD28/B7 costimulatory interactions, and subsequently leading to direct activation and expansion of effector T cells which can target cancer antigens [28,29,30]. This evidence concerns the gene CTLA4 and neoplasm.